PPibarot Profile Banner
Philippe Pibarot Profile
Philippe Pibarot

@PPibarot

Followers
7K
Following
1K
Media
259
Statuses
2K

Proud father, husband, rock and ice climber, and clinical scientist and professor passionate about valvular heart disease and cardiovascular imaging

Québec, Canada
Joined February 2017
Don't wanna be here? Send us removal request.
@PPibarot
Philippe Pibarot
4 months
Such an important editorial - A Must Read: Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come
0
3
22
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: The Heart Valve Society and Its Journal Finally Meet – The Future Is Bright. In the first inaugural issue of the #Journal….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: ✨Just published in the first issue of the #JHVS: 3-year results of the AVIATOR REGISTRY🫀 including 2,206 patients with ao….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Delve into the intricate dynamics of the extracellular matrix in the aortic valve, particularly on its role in health and….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of #JHVS: Women with small aortic annulus are less likely to experience prosthesis-pati….
0
4
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Approximately 9% of the patients with severe AS also had PAD. Notably, these patients faced a significantly higher risk o….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of the #JHVS: Cardiovascular magnetic resonance as a non-invasive tool to assess myocar….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of JHVS: Focus on the complex interplay between cardiac amyloidosis and aortic stenosis….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of #JHVS: Intersection of AS and chronic kidney disease (CKD): a call to action for cli….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: The role of multimodality imaging in assessing AS and the challenges and advancements in diagnosing AS. The review emphas….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of #JHVS: The Ross procedure in adults, a surgical technique that has gained renewed in….
0
3
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: The Aortic Valve Research Network Investigators presents the Heart Valve Society Aortic Valve Database, which is a pivota….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Challenging the recently introduced concept of extra-valvular cardiac damage staging in #HVD by introducing the importanc….
0
3
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: 🥊Just published in the first issue of #JHVS: Which is the best modality to assess bioprosthetic valve hemodynamic functio….
0
4
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of #JHVS: Cahalane et al. present the mission of the recently launched young investigat….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in this first issue of the #JHVS: The first ICHOM standards for the reporting of patient-centered outcomes….
0
2
0
@PPibarot
Philippe Pibarot
4 months
RT @OfValve76696: Just published in the first issue of #JHVS: In-memoriam🕊️article to underline the outstanding career and contribution of….
0
2
0
@PPibarot
Philippe Pibarot
5 months
Dear followers I will not post anymore on X. I encourage you to follow me on BlueSky or LinkedIn. Thank you for your support. Chers followers, à partir d’aujourd’hui je n’utiliserai plus la plateforme X. Je vous encourage à me suivre sur BlueSky et LinkedIn. Merci.
0
1
3
@PPibarot
Philippe Pibarot
6 months
Very proud and honored to be in 2024 for the seventh consecutive year among the most influential scientists in clinical medicine. I am so grateful to my wonderful team @IUCPQ
Tweet media one
3
1
41
@PPibarot
Philippe Pibarot
8 months
TAVR UNLOAD just presented at TCT. First RCT in moderate AS and HFrEF. The trial did not meet the primary endpoint at last FU but early TAVR was superior to clinical surveillance at 1 year.
Tweet media one
Tweet media two
Tweet media three
3
14
56